Tuberculosis drug discovery and emerging targets

Annals of the New York Academy of Sciences

Volumn 1323, Issue 1, 2014, Pages 56-75

  Mdluli, Khisimuzi ^a   Kaneko, Takushi ^a   Upton, Anna ^a  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

Drug discovery; Drug regimens; Mycobacterium tuberculosis; Nonreplicating; Tuberculosis drugs

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMIDE; ANTIINFECTIVE AGENT; CHOLESTEROL; ENDOPEPTIDASE CLP; IMIDAZOPYRIDINE DERIVATIVE; IRON; NATURAL PRODUCT; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; TUBERCULOSTATIC AGENT; UREA DERIVATIVE;

ARTICLE; CARBON METABOLISM; CHOLESTEROL METABOLISM; DRUG DESIGN; DRUG RESISTANT TUBERCULOSIS; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENERGY; HUMAN; IRON STORAGE; LUNG TUBERCULOSIS; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; RESPIRATORY CHAIN; SCREENING; SYNTHESIS; TREATMENT DURATION; CHEMISTRY; DRUG DEVELOPMENT; DRUG REGIMENS; NONREPLICATING; REVIEW; TUBERCULOSIS; TUBERCULOSIS DRUGS;

DRUG DISCOVERY; DRUG REGIMENS; MYCOBACTERIUM TUBERCULOSIS; NONREPLICATING; TUBERCULOSIS DRUGS;

ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HUMANS; TUBERCULOSIS;

EID: 84907958794     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12459     Document Type: Article

References (194)

1. Cole, S.T., R. Brosch, J. Parkhill, et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
2. Sassetti, C.M. & E.J. Rubin . 2003. Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. U. S. A. 100: 12989-12994.
3. Sassetti, C.M., D.H. Boyd & E.J. Rubin . 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48: 77-84.
4. Zhang, Y.J., T.R. Ioerger, C. Huttenhower, et al. 2012 Global assessment of genomic regions required for growth in Mycobacterium tuberculosis. PLoS Pathog. 8: e1002946.
5. Sherman, D.R., M. Voskuil, D. Schnappinger, et al. 2001. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc. Natl. Acad. Sci. U. S. A. 98: 7534-7539.
6. Rustad, T.R., M.I. Harrell, R. Liao & D.R. Sherman . 2008. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One 3: e1502.
7. Schnappinger, D., S. Ehrt, M.I. Voskuil, et al. 2003 Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J. Exp. Med. 198: 693-704.
8. Ioerger, T.R., T. O'Malley, R. Liao, et al. 2013. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One 8: e75245.
9. Remuiñán, M.J., E. Pérez-Herrán, J. Rullás, et al. 2013. Tetrahydropyrazolo[1, 5-a]pyrimidine-3-carboxamide and N-benzyl-6′, 7′-dihydrospiro[piperidine-4, 4′-thieno[3, 2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PLoS One 8: e60933.
10. Abrahams, K.A., J.A. Cox, V.L. Spivey, et al. 2012. Identification of novel imidazo[1, 2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS One 7: e52951.
11. La Rosa, V., G. Poce, J.O. Canseco, et al. 2012. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56: 324-331.
12. Woong Park, S., M. Klotzsche, D.J. Wilson, et al. 2011. Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog. 7: e1002264.
13. Wei, J.R., V. Krishnamoorthy, K. Murphy, et al. 2011. Depletion of antibiotic targets has widely varying effects on growth. Proc. Natl. Acad. Sci. U. S. A. 108: 4176-4181.
14. FDA News Release, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm.
15. Wall Street Journal, http://online.wsj.com/article/PR-CO-20131125--900844.html.
16. Details for projects listed can be found at: http://www.newtbdrugs.org/pipeline.php and ongoing. Projects without a lead compound series identified can be viewed at: http://www.newtbdrugs.org/pipeline-discovery.php.
17. Payne, D.J., M.N. Gwynn, D.J. Holmes & D.L. Pompliano . 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6: 29-40.
18. Andries, K., P. Verhasselt, J. Guillemont, et al. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
19. Stanley, S.A., T. Kawate, N. Iwase, et al. 2013. Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32. Proc. Natl. Acad. Sci. U. S. A. 110: 11565-11570.
20. Kawate, T., N. Iwase, M. Shimizu, et al. 2013. Synthesis and structure-activity relationships of phenyl-substituted coumarins with anti-tubercular activity that target FadD32. Bioorg. Med. Chem. Lett. 23: 6052-6059.
21. Rao, S.P., S.B. Lakshminarayana, R.R. Kondreddi, et al. 2013. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci. Transl. Med. 5: 214ra168.
22. Ananthan, S., E.R. Faaleolea, R.C. Goldman, et al. 2009. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb). 89: 334-353.
23. Maddry, J.A., S. Ananthan, R.C. Goldman, et al. 2009. Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb). 89: 354-363.
24. Ballell, L., R.H. Bates, R.J. Young, et al. 2013. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMedChem. 8: 313-321.
25. Yokokawa, F., G. Wang, W.L. Chan, et al. 2013. Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active novel anti-tubercular agents. ACS Chem. Lett. 4: 451-455.
26. Kondreddi, R.R., J. Jiricek, S.P.S. Rao, et al. 2013. Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents. J. Med. Chem. 56: 8849-8859.
27. Ramachandran, S., M. Panda, K. Mukherjee, et al. 2013. Synthesis and structure activity relationship of imidazo[1, 2-a]pyridine-8-carboxamides as a novel antimycobacterial lead series. Bioorg. Med. Chem. Lett. 23: 4996-5001.
28. Christophe, T., F. Ewann, H.K. Jeon, et al. 2010. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. Future Med. Chem. 2: 1283-1293.
29. Pethe, K., P. Bifani, J. Jang, et al. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19: 1157-1160.
30. Mak, P.A., S.P. Rao, M. Ping Tan, et al. 2012. A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem. Biol. 7: 1190-1197.
31. Darby, C.M., H.I. Ingólfsson, X. Jiang, et al. 2013. Whole cell screen for inhibitors of pH homeostasis in Mycobacterium tuberculosis. PLoS One 8: e68942.
32. Kumar, A., A. Casey, J. Odingo, et al. 2013. A high-throughput screen against pantothenate synthetase (PanC) identifies 3-biphenyl-4-cyanopyrrole-2-carboxylic acids as a new class of inhibitor with activity against Mycobacterium tuberculosis. PLoS One 8: e72786.
33. Moraski, G.C., L.D. Markley, P.A. Hipskind, et al. 2011. Advent of Imidazo[1, 2-a]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity. ACS Med. Chem. Lett. 2: 466-470.
34. Moraski, G.C., L.D. Markley, M. Chang, et al. 2012. Generation and exploration of new classes of antitubercular agents: the optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1, 2-a]pyridines and isomeric 5, 6-fused scaffolds. Bioorg. Med. Chem. 20: 2214-2220.
35. Brown, J.R., E.J. North, J.G. Hurdle, et al. 2011. The structure-activity relationship of urea derivatives as anti-tuberculosis agents. Bioorg. Med. Chem. 19: 5585-5595.
36. Scherman, M.S., E.J. North, V. Jones, et al. 2012. Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability. Bioorg. Med. Chem. 20: 3255-3262.
37. Batt, S.M., T. Jabeen, V. Bhowruth, et al. 2012. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl. Acad. Sci. U. S. A. 109: 11354-11359.
38. Grzegorzewicz, A.E., H. Pham, V.A. Gundi, et al. 2012. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8: 334-341.
39. Stanley, S.A., S.S. Grant, T. Kawate, et al. 2012. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7: 1377-1384.
40. Goldman, R.C. 2013. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Tuberculosis (Edinb). 93: 569-588.
41. Chen, M., J. Borlak & W. Tong . 2013. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 58: 388-396.
42. Naven, R.T., R. Swiss, J. Klug-McLeod, et al. 2013. The development of structure-activity relationships for mitochondrial dysfunction: uncoupling of oxidative phosphorylation. Toxicol. Sci. 131: 271-278.
43. Tarcsay, Á. & G.M. Keseru . 2013. Contributions of molecular properties to drug promiscuity. J. Med. Chem. 56: 1789-1795.
44. Bhat, J., A. Narayan, J. Venkatraman & M. Chatterji . 2013. LC-MS based assay to measure intracellular compound levels in Mycobacterium smegmatis: linking compound levels to cellular potency. J. Microbiol. Methods 94: 152-158.
45. Sarathy, J.P., V. Dartois & E.J. Lee . 2012. The role of transport mechanisms in mycobacterium tuberculosis drug resistance and tolerance. Pharmaceuticals (Basel). 5: 1210-1235.
46. Siroy, A., C. Mailaender, D. Harder, et al. 2008. Rv1698 of Mycobacterium tuberculosis represents a new class of channel-forming outer membrane proteins. J. Biol. Chem. 283: 17827-1737.
47. Personal communication with Ujjini Manjunatha, Paul Smith et al. (manuscript in preparation).
48. Ishizaki, Y., C. Hayashi, K. Inoue, et al. 2013. Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45. J. Biol. Chem. 288: 30309-30319.
49. Newman, D.J. & G.M. Cragg . 2012. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75: 311-335.
50. García, A., V. Bocanegra-García, J.P. Palma-Nicolás & G. Rivera . 2012. Recent advances in antitubercular natural products. Eur. J. Med. Chem. 49: 1-23.
51. Salomon, C.E. & L.E. Schmidt . 2012. Natural products as leads for tuberculosis drug development. Curr. Top Med. Chem. 12: 735-765.
52. Guzman, J.D., A. Gupta, F. Bucar, et al. 2012. Antimycobacterials from natural sources: ancient times, antibiotic era and novel scaffolds. Front Biosci. (Landmark Ed). 17: 1861-1881.
53. Kirst, H.A. 2013. Developing new antibacterials through natural product research. Expert Opin. Drug Discov. 8: 479-493.
54. Singh, S.B., K. Young & L. Miesel . 2011. Screening strategies for discovery of antibacterial natural products. Expert Rev. Anti Infect. Ther. 9: 589-613.
55. Steinmetz, H., H. Irschik, B. Kunze, et al. 2007. Thuggacins, macrolide antibiotics active against Mycobacterium tuberculosis: isolation from myxobacteria, structure elucidation, conformation analysis and biosynthesis. Chemistry 13: 5822-5832.
56. Irschik, H., H. Reichenbach, G. Höfle & R. Jansen . 2007. The thuggacins, novel antibacterial macrolides from Sorangium cellulosum acting against selected Gram-positive bacteria. J. Antibiot. (Tokyo) 60: 733-738.
57. Truong, N.B., C.V. Pham, H.T. Doan, et al. 2011. Antituberculosis cycloartane triterpenoids from Radermachera boniana. J. Nat. Prod. 74: 1318-1322.
58. Pruksakorn, P., M. Arai, N. Kotoku, et al. 2010. Trichoderins, novel aminolipopeptides from a marine sponge-derived Trichoderma sp., are active against dormant mycobacteria. Bioorg. Med. Chem. Lett. 20: 3658-3663.
59. Pruksakorn, P., M. Arai, L. Liu, et al. 2011. Action-mechanism of trichoderin A, an anti-dormant mycobacterial aminolipopeptide from marine sponge-derived Trichoderma sp. Biol. Pharm. Bull. 34: 1287-1290.
60. Iwatsuki, M., R. Uchida, Y. Takakusagi, et al. 2007. Lariatins, novel anti-mycobacterial peptides with a lasso structure, produced by Rhodococcus jostii K01-B0171. J. Antibiot. (Tokyo) 60: 357-363.
61. Iwatsuki, M., H. Tomoda, R. Uchida, et al. 2006. Lariatins, antimycobacterial peptides produced by Rhodococcus sp. K01-B0171, have a lasso structure. J. Am. Chem. Soc. 128: 7486-7491.
62. Hartkoorn, R.C., C. Sala, J. Neres, et al. 2012. Towards a new tuberculosis drug: pyridomycin-nature's isoniazid. EMBO Mol. Med. 4: 1032-1042.
63. Hartkoorn, R.C., F. Pojer, J.A. Read, et al. 2013. Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA. Nat. Chem. Biol. 10: 96-98.
64. Finn, J. 2012. Application of SBDD to the discovery of new antibacterial drugs. Methods Mol. Biol. 841: 291-319.
65. Krieger, I.V., J.S. Freundlich, V.B. Gawandi, et al. 2012. Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase. Chem. Biol. 19: 1556-1567.
66. Pan, P. & P.J. Tonge . 2012. Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. Curr. Top Med. Chem. 12: 672-693.
67. Ballell Pages, L., J. Castro Pichel, R. Fernandez Menendez, et al. 2010. (Pyrazol-3-yl)-1, 3, 4-thiadiazole-2-amine and(Pyrazol-3-yl)-1, 3, 4-thiazole-2-amine Compounds. PCT publicationNo. WO 2010/118852 A1.
68. Castro Pichel, J., R. Fernandez Menendez, E.P. Fernandez Velando, et al. 2012. 3-Amino-Pyrazole Derivatives Useful Against Tuberculosis. PCT publication No. WO2012/049161 A1.
69. Shirude, P.S., P. Madhavapeddi, M. Naik, et al. 2013. Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis. J. Med. Chem. 56: 8533-8542.
70. Encinas, L.1., H. O'Keefe, M. Neu, et al. 2014. Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of mycobacterium tuberculosis InhA. J. Med. Chem. 57: 1276-1288.
71. Silvestre, H.L., T.L. Blundell, C. Abell & A. Ciulli . 2013. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc. Natl. Acad. Sci. U. S. A. 110: 12984-12989.
72. Hung, A.W., H.L. Silvestre, S. Wen, et al. 2009. Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew. Chem. Int. Ed. Engl. 48: 8452-8456.
73. Doherty, C.P. 2007. Host-pathogen interactions: the role of iron. J. Nutr. 137: 1341-1344.
74. Johnson, E.E. & M. Wessling-Resnick . 2012. Iron metabolism and the innate immune response to infection. Microbes Infect. 14: 207-216.
75. Weinberg, E.D. 1999. Iron loading and disease surveillance. Emerg. Infect. Dis. 5: 346-352.
76. Kauffmann, S.H.E. 2004. New issues in tuberculosis. Ann. Rheum. Dis. 63: 1150-1156.
77. Rodriguez, G.M. 2006. Control of iron metabolism in Mycobacterium tuberculosis. Trends Microbiol. 14: 320-327.
78. Ratledge, C. & L.G. Dover . 2000. Iron metabolism in pathogenic bacteria. Annu. Rev. Microbiol. 54: 881-941.
79. Reddy, P.V., R.V. Puri, P. Chauhan, et al. 2013. Disruption of mycobactin biosynthesis leads to attenuation of Mycobacterium tuberculosis for growth and virulence. J. Infect. Dis. 208: 1255-1265.
80. Neres, J., N.P. Labello, R.V. Somu, et al. 2008. Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5′-O-[N-(salicyl)sulfamoyl]adenosine. J. Med. Chem. 51: 5349-5370.
81. Rodriguez, G.M. & I. Smith . 2006. Identification of an ABC transporter required for iron acquisition and virulence in Mycobacterium tuberculosis. J. Bacteriol. 188: 424-430.
82. Siegrist, M.S., M. Unnikrishnan, M.J. McConnell, et al. 2009. Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. Proc. Natl. Acad. Sci. U. S. A. 106: 18792-18797.
83. Wells, R.M., C.M. Jones, Z. Xi, et al. 2013. Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis. PLoS Pathog. 9: e1003120.
84. Tullius, M.V., C.A. Harmston, C.P. Owens, et al. 2011. Discovery and characterization of a unique mycobacterial heme acquisition system. Proc. Natl. Acad. Sci. U. S. A. 108: 5051-5056.
85. Owens, C.P., N. Chim, A.B. Graves, et al. 2013. The Mycobacterium tuberculosis secreted protein Rv0203 transfers heme to membrane proteins MmpL3 and MmpL11. J. Biol. Chem. 288: 21714-21728.
86. Gupta, V., R.K. Gupta, G. Khare, et al. 2008. Cloning, expression, purification, crystallization and preliminary X-ray crystallographic analysis of bacterioferritin A from Mycobacterium tuberculosis. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 64(Pt 5): 398-401.
87. McMath, L.M., J.E. Habel, B. Sankaran, et al. 2010. Crystallization and preliminary X-ray crystallographic analysis of a Mycobacterium tuberculosis ferritin homolog, BfrB. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 66(Pt 12): 1657-1661.
88. Reddy, P.V., R.V. Puri, A. Khera & A.K. Tyagi . 2012. Iron storage proteins are essential for the survival and pathogenesis of Mycobacterium tuberculosis in THP-1 macrophages and the guinea pig model of infection. J. Bacteriol. 194: 567-575.
89. Pandey, R. & G.M. Rodriguez . 2012. A ferritin mutant of Mycobacterium tuberculosis is highly susceptible to killing by antibiotics and is unable to establish a chronic infection in mice. Infect. Immun. 80: 3650-3659.
90. Engelhart, C.A. & C.C. Aldrich . 2013. Synthesis of chromone, quinolone, and benzoxazinone sulfonamide nucleosides as conformationally constrained inhibitors of adenylating enzymes required for siderophore biosynthesis. J. Org. Chem. 78: 7470-7481.
91. Mai, D., J. Jones, J.W. Rodgers, et al. 2011. A screen to identify small molecule inhibitors of protein-protein interactions in mycobacteria. Assay Drug Dev. Technol. 9: 299-310.
92. Monfeli, R.R. & C. Beeson . 2007. Targeting iron acquisition by Mycobacterium tuberculosis. Infect. Disord. Drug Targets 7: 213-220.
93. Holmes, M.A., W. Paulsene, X. Jide, et al. 2005. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure 13: 29-41.
94. Paulsen, I.T., M. H. Brown & R.A. Skurray . 1996. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60: 575-608.
95. Putman, M., H.W. van Veen & W.N. Konings . 2000. Molecular properties of bacterial multidrug transporters. Microbiol. Mol. Biol. Rev. 64: 672-693.
96. Domenech, P., M.B. Reed & C.E. Barry 3rd. 2005. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect. Immun. 73: 3492-3501.
97. Cox, J.S., B. Chen, M. McNeil & W.R. Jacobs, Jr. 1999. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 402: 79-83.
98. Jain, M. & J.S. Cox . 2005. Interaction between polyketide synthase and transporter suggests coupled synthesis and export of virulence lipid in M. tuberculosis. PLoS Pathog. 1: e2.
99. Domenech, P., M.B. Reed, C.S. Dowd, et al. 2004. The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J. Biol. Chem. 279: 21257-21265.
100. Lamichhane, G., S. Tyagi & W.R. Bishai . 2005. Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs. Infect. Immun. 73: 2533-2540.
101. Tahlan, K., R. Wilson, D.B. Kastrinsky, et al. 2012. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56: 1797-1809.
102. Grzegorzewicz, A.E., J. Korduláková, V. Jones, et al. 2012. A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. J. Biol. Chem. 287: 38434-38441.
103. Varela, C., D. Rittmann, A. Singh, et al. 2012. MmpL genes are associated with mycolic acid metabolism in mycobacteria and corynebacteria. Chem. Biol. 19: 498-506.
104. Milano, A., M.R. Pasca, R. Provvedi, et al. 2009. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb) 89: 84-90.
105. Nesbitt, N.M., X. Yang, P. Fontán, et al. 2010. A thiolase of Mycobacterium tuberculosis is required for virulence and production of androstenedione and androstadienedione from cholesterol. Infect. Immun. 78: 275-282.
106. Yam, K.C., I. D'Angelo, R. Kalscheuer, et al. 2009. Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis. PLoS Pathog. 5: e1000344.
107. Chang, J.C., M.D. Miner, A.K. Pandey, et al. 2009. igr Genes and Mycobacterium tuberculosis cholesterol metabolism. J. Bacteriol. 191: 5232-5239.
108. Pandey, A.K. & C.M. Sassetti . 2008. Mycobacterial persistence requires the utilization of host cholesterol. Proc. Natl. Acad. Sci. U. S. A. 105: 4376-4380.
109. Miner, M.D., J.C. Chang, A.K. Pandey, et al. 2009. Role of cholesterol in Mycobacterium tuberculosis infection. Indian J. Exp. Biol. 47: 407-411.
110. Van der Geize, R., K. Yam, T. Heuser, et al. 2007. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc. Natl. Acad. Sci. U. S. A. 104: 1947-1952.
111. Kim, M.J. et al. 2010. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol. Med. 2: 258-274.
112. Schafer, G. et al. 2009. The role of scavenger receptor B1 in infection with Mycobacterium tuberculosis in a murine model. PLoS One 4: e8448.
113. Gatfield, J. & J. Pieters . 2000. Essential role for cholesterol in entry of mycobacteria into macrophages. Science 288: 1647-1650.
114. Peyron, P. et al. 2000. Nonopsonic phagocytosis of Mycobacterium kansasii by human neutrophils depends on cholesterol and is mediated by CR3 associated with glycosylphosphatidylinositolanchored proteins. J. Immunol. 165: 5186-5191.
115. Chang, J.C., N.S. Harik, R.P. Liao & D.R. Sherman . 2007. Identification of Mycobacterial genes that alter growth and pathology in macrophages and in mice. J. Infect. Dis. 196: 788-795.
116. Thomas, S.T., B.C. VanderVen, D.R. Sherman, et al. 2011. Pathway profiling in Mycobacterium tuberculosis: elucidation of cholesterol-derived catabolite and enzymes that catalyze its metabolism. J. Biol. Chem. 286: 43668-43678.
117. Capyk, J.K., I. Casabon, R.Gruninger, et al. 2011. Activity of 3-ketosteroid 9α-hydroxylase (KshAB) indicates cholesterol side chain and ring degradation occur simultaneously in Mycobacterium tuberculosis. J. Biol. Chem. 286: 40717-40724.
118. Rengarajan, J., B.R. Bloom & E.J. Rubin . 2005. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc. Natl. Acad. Sci. U. S. A. 102: 8327-8332.
119. Lack, N.A., K.C. Yam, E.D. Lowe, et al. 2010. Characterization of a carbon-carbon hydrolase from Mycobacterium tuberculosis involved in cholesterol metabolism. J. Biol. Chem. 285: 434-443.
120. Dresen, C., L.Y. Lin, I. D'Angelo, et al. 2010. A flavin-dependent monooxygenase from Mycobacterium tuberculosis involved in cholesterol catabolism. J. Biol. Chem. 285: 22264-22275.
121. Casabon, I., A.M. Crowe, J. Liu & L.D. Eltis . 2013. FadD3 is an acyl-CoA synthetase that initiates catabolism of cholesterol rings C and D in actinobacteria. FadD3 is an acyl-CoA synthetase that initiates catabolism of cholesterol rings C and D in actinobacteria. Mol. Microbiol. 87: 269-283.
122. Mohn, W.W., R. van der Geize, G.R. Stewart, et al. 2008. The actinobacterial mce4 locus encodes a steroid transporter. J. Biol. Chem. 283: 35368-35374.
123. Senaratne, R.H., B. Sidders, P. Sequeira, et al. 2008. Mycobacterium tuberculosis strains disrupted in mce3 and mce4 operons are attenuated in mice. J Med Microbiol. 57(Pt 2): 164-170.
124. Yang, X., J. Gao, I. Smith, et al. 2011. Cholesterol is not an essential source of nutrition for Mycobacterium tuberculosis during infection. J. Bacteriol. 193: 1473-1476.
125. Brötz-Oesterhelt, H., D. Beyer, H.P. Kroll, et al. 2005. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. 11: 1082-1087.
126. Ingvarsson, H., M.J. Maté, M. Högbom, et al. 2007. Insights into the inter-ring plasticity of caseinolytic proteases from the X-ray structure of Mycobacterium tuberculosis ClpP1. Acta Crystallogr. D Biol. Crystallogr. 63(Pt 2): 249-259.
127. Sherrid, A.M., T.R. Rustad, G.A. Cangelosi & D.R. Sherman . 2010. Characterization of a Clp protease gene regulator and the reaeration response in Mycobacterium tuberculosis. PLoS One 5: e11622.
128. Estorninho, M., H. Smith, J. Thole, et al. 2010. ClgR regulation of chaperone and protease systems is essential for Mycobacterium tuberculosis parasitism of the macrophage. Microbiology 156(Pt 11): 3445-3455.
129. Ollinger, J., T. O'Malley, E.A. Kesicki, et al. 2012. Validation of the essential ClpP protease in Mycobacterium tuberculosis as a novel drug target. J. Bacteriol. 194: 663-668.
130. Kirstein, J., A. Hoffmann, H. Lilie, et al. 2009. The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease. EMBO Mol. Med. 1: 37-49.
131. Conlon, B.P., E.S. Nakayasu, L.E. Fleck, et al. 2013. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503: 365-370.
132. Compton, C.L., K.R. Schmitz, R.T. Sauer & J.K. Sello . 2013. Antibacterial activity of and resistance to small molecule inhibitors of the ClpP peptidase. ACS Chem. Biol. 8: 2669-2677.
133. Rhee, K.Y., L.P. de Carvalho, R. Bryk, et al. 2011. Central carbon metabolism in Mycobacterium tuberculosis: an unexpected frontier. Trends Microbiol. 19: 307-314.
134. Höner Zu Bentrup, K., A. Miczak, D.L. Swenson & D.G. Russell . 1999. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J. Bacteriol. 181: 7161-7167.
135. Smith, C.V., C.C. Huang, A. Miczak, et al. 2003. Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis. J. Biol. Chem. 278: 1735-1743.
136. McKinney, J.D., K. Höner zu Bentrup, E.J. Muñoz-Elías, et al. 2000. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406: 735-738.
137. Muñoz-Elías, E.J. & J.D. McKinney . 2005. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat. Med. 11: 638-644.
138. Timm, J., F.A. Post, L.G. Bekker, et al. 2003. Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc. Natl. Acad. Sci. U. S. A. 100: 14321-14326.
139. Muñoz-Elías, E.J., A.M. Upton, J. Cherian & J.D. McKinney . 2006. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol. Microbiol. 60: 1109-1122.
140. Gould, T.A., H. van de Langemheen, E.J. Muñoz-Elías, et al. 2006. Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium tuberculosis. Mol. Microbiol. 61: 940-947.
141. Gengenbacher, M., S.P. Rao, K. Pethe & T. Dick . 2010. Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology 156(Pt 1): 81-87.
142. Eoh, H. & K.Y. Rhee . 2013. Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 110: 6554-6559.
143. Sharma, V., S. Sharma, K. Hoener zu Bentrup, et al. 2000. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat. Struct. Biol. 7: 663-668.
144. Krátký, M. & J. Vinšová . 2012. Advances in mycobacterial isocitrate lyase targeting and inhibitors. Curr. Med. Chem. 19: 6126-6137.
145. Abrahams, G.L., A. Kumar, S. Savvi, et al. 2012. Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem. Biol. 19: 844-854.
146. 13C metabolic flux analysis identifies an unusual route for pyruvate dissimilation in mycobacteria which requires isocitrate lyase and carbon dioxide fixation. PLoS Pathog. 7: e1002091.
147. de Carvalho, L.P., S.M. Fischer, J. Marrero, et al. 2010. Metabolomics of Mycobacterium tuberculosis reveals compartmentalized co-catabolism of carbon substrates. Chem. Biol. 17: 1122-1131.
148. Griffin, J.E., J.D. Gawronski, M.A. Dejesus, et al. 2011. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog. 7: e1002251.
149. Marrero, J., K.Y. Rhee, D. Schnappinger, et al. 2010. Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc. Natl. Acad. Sci. U. S. A. 107: 9819-9824.
150. Liu, K., J. Yu & D.G. Russell . 2003. pckA-deficient Mycobacterium bovis BCG shows attenuated virulence in mice and in macrophages. Microbiology 149(Pt 7): 1829-1835.
151. Mukhopadhyay, B., E.M. Concar & R.S. Wolfe . 2001. A GTP-dependent vertebrate-type phosphoenolpyruvate carboxykinase from Mycobacterium smegmatis. J. Biol. Chem. 276: 16137-16145.
152. Marrero, J., C. Trujillo, K.Y. Rhee & S. Ehrt . 2013. Glucose phosphorylation is required for Mycobacterium tuberculosis persistence in mice. PLoS Pathog. 9: e1003116.
153. Tian, J., R. Bryk, S. Shi, et al. 2005. Mycobacterium tuberculosis appears to lack alpha-ketoglutarate dehydrogenase and encodes pyruvate dehydrogenase in widely separated genes. Mol. Microbiol. 57: 859-868.
154. Bryk, R., C.D. Lima, H. Erdjument-Bromage, et al. 2002. Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein. Science 295: 1073-1077.
155. Bryk, R., P. Griffin & C. Nathan . 2000. Peroxynitrite reductase activity of bacterial peroxiredoxins. Nature 407: 211-215.
156. Venugopal, A., R. Bryk, S. Shi, et al. 2011. Virulence of Mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multienzyme complexes. Cell Host Microbe. 9: 21-31.
157. Shi, S. & S. Ehrt . 2006. Dihydrolipoamide acyltransferase is critical for Mycobacterium tuberculosis pathogenesis. Infect. Immun. 74: 56-63.
158. Bryk, R., N. Arango, A. Venugopal, et al. 2010. Triazaspirodimethoxybenzoyls as selective inhibitors of mycobacterial lipoamide dehydrogenase. Biochemistry 49: 1616-1627.
159. Bryk, R., B. Gold, A. Venugopal, et al. 2008. Selective killing of nonreplicating mycobacteria. Cell Host Microbe. 3: 137-145.
160. Kalscheuer, R. & W.R. Jacobs, Jr. 2010. The significance of GlgE as a new target for tuberculosis. Drug News Perspect. 23: 619-624.
161. Diacon, A.H., A. Pym, M. Grobusch, et al. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360: 2397-2405.
162. Zhang, Y., M.M. Wade, A. Scorpio, et al. 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52: 790-795.
163. Koul, A., L. Vranckx, N. Dendouga, et al. 2008. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283: 25273-25280.
164. Rao, S.P., S. Alonso, L. Rand, et al. 2008. The proton motive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 105: 11945-11950.
165. Kana, B.D., E.A. Weinstein, D. Avarbock, et al. 2001. Characterization of the cydAB-encoded cytochrome bd oxidase from Mycobacterium smegmatis. J. Bacteriol. 183: 7076-7086.
166. Matsoso, L.G., B.D. Kana, P.K. Crellin, et al. 2005. Function of the cytochrome bc1-aa3 branch of the respiratory network in mycobacteria and network adaptation occurring in response to its disruption. J. Bacteriol. 187: 6300-6308.
167. Weinstein, E.A., T. Yano, L.S. Li, et al. 2005. Inhibitors of type II NADH: menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl. Acad. Sci. U. S. A. 102: 4548-4553.
168. Small, J.L., S.W. Park, B.D. Kana, et al. 2013. Perturbation of cytochrome c maturation reveals adaptability of the respiratory chain in Mycobacterium tuberculosis. MBio. 4: e00475-13.
169. Watanabe, S., M. Zimmermann, M.B. Goodwin, et al. 2011. Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog. 7: e1002287.
170. Bettencourt, M.V., S. Bosne-David & L. Amaral . 2000. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 16: 69-71.
171. Amaral, L., J.E. Kristiansen, L.S. Abebe & W. Millett . 1996. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother. 38: 1049-1053.
172. Warman, A.J., T.S. Rito, N.E. Fisher, et al. 2013. Antitubercular pharmacodynamics of phenothiazines. J. Antimicrob. Chemother. 68: 869-880.
173. Yano, T., S. Kassovska-Bratinova, J.S. Teh, et al. 2011. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J. Biol. Chem. 286: 10276-10287.
174. McAdam, R.A., S. Quan, D.A. Smith, et al. 2002. Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence. Microbiology 148(Pt 10): 2975-2986.
175. Dhiman, R.K., S. Mahapatra, R.A. Slayden, et al. 2009. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Mol. Microbiol. 72: 85-97.
176. Kurosu, M. & D.C. Crick . 2009. MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis. Med. Chem. 5: 197-207.
177. Li, X., N. Liu, H. Zhang, et al. 2011. CoA adducts of 4-Oxo-4-Phenylbut-2-enoates: inhibitors of MenB from the M. tuberculosis Menaquinone Biosynthesis Pathway. ACS Med. Chem. Lett. 2: 818-823.
178. Debnath, J., S. Siricilla, B. Wan, et al. 2012. Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis. J. Med. Chem. 55: 3739-3755.
179. Kurosu, M., P. Narayanasamy, K. Biswas, et al. 2007. Discovery of 1, 4-dihydroxy-2-naphthoate prenyltransferase inhibitors: new drug leads for multidrug-resistant Gram-positive pathogens. J. Med. Chem. 50: 3973-3974.
180. Lu, X., R. Zhou, I. Sharma, et al. 2012. Stable analogues of OSB-AMP: potent inhibitors of MenE, the o-Succinylbenzoate-CoA synthetase from bacterial menaquinone biosynthesis. Chembiochem. 13: 129-136.
181. Moraski, G.C., L.D. Markley, J. Cramer, et al. 2013. Advancement of Imidazo[1, 2-a]pyridines with improved pharmacokinetics and nanomolar activity against Mycobacterium tuberculosis. ACS Med. Chem. Lett. 4: 675-679.
182. Keren, I., Y. Wu, J. Inocencio, et al. 2013. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 339: 1213-1216.
183. Dwyer, D.J., M.A. Kohanski & J.J. Collins . 2009. Role of reactive oxygen species in antibiotic action and resistance. Curr. Opin. Microbiol. 12: 482-489.
184. Grant, S.S., B.B. Kaufmann, N.S. Chand, et al. 2012. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc. Natl. Acad. Sci. U. S. A. 109: 12147-12152.
185. Via, L.E., P.L. Lin, S.M. Ray, et al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76: 2333-2340.
186. Singh, R., U. Manjunatha, H.I. Boshoff, et al. 2008. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322: 1392-1395.
187. Gurumurthy, M., M. Rao, T. Mukherjee, et al. 2013. A novel F(420) -dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents. Mol. Microbiol. 87: 744-755.
188. Domann, F.E. 2013. Aberrant free radical biology is a unifying theme in the etiology and pathogenesis of major human diseases. Int. J. Mol. Sci. 14: 8491-8495.
189. Orme, I.M. 2014. A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis (Edinb) 94: 8-14.
190. Lin, P.L., C.B. Ford, M.T. Coleman, et al. 2014. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat. Med. 20: 75-79.
191. Dartois, V. & C.E. Barry 3rd. 2013. A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg. Med. Chem. Lett. 23: 4741-4750.
192. Kjellsson, M.C., L.E. Via, A. Goh, et al. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 56: 446-457.
193. Pai, S.R., J.K. Actor, E. Sepulveda, et al. 2000. Identification of viable and non-viable Mycobacterium tuberculosis in mouse organs by directed RT-PCR for antigen 85B mRNA. Microb. Pathog. 28: 335-342.
194. Manina, G. & J.D. McKinney . 2013. A single-cell perspective on non-growing but metabolically active (NGMA) bacteria. Curr. Top Microbiol. Immunol. 374: 135-161.